NCT03922542 Comparison of Standard vs. Accelerated Corneal Crosslinking
| NCT ID | NCT03922542 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Price Vision Group |
| Condition | Keratoconus |
| Study Type | INTERVENTIONAL |
| Enrollment | 510 participants |
| Start Date | 2019-04-16 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 510 participants in total. It began in 2019-04-16 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
Eligibility Criteria
Inclusion Criteria: * Documented keratoconus or ectasia after refractive surgery Exclusion Criteria: * Insufficient corneal thickness * Ocular condition that may predispose the eye to complications * History of chemical injury or delayed epithelial healing * Condition that would interfere with or prolong epithelial healing * Known sensitivity to treatment medications * Pregnancy
Contact & Investigator
Francis W Price, Jr., MD
PRINCIPAL INVESTIGATOR
Price Vision Group
Frequently Asked Questions
Who can join the NCT03922542 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, studying Keratoconus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03922542 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT03922542 currently recruiting?
Yes, NCT03922542 is actively recruiting participants. Contact the research team at mprice@cornea.org for enrollment information.
Where is the NCT03922542 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT03922542 clinical trial?
NCT03922542 is sponsored by Price Vision Group. The principal investigator is Francis W Price, Jr., MD at Price Vision Group. The trial plans to enroll 510 participants.